COMPASS PATHWAYS PLC Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
COMPASS PATHWAYS PLC (CMPS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $6.19 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-24
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $10.38, a 2.98% increase year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $10.08, a 31.94% decline year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $14.81.
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $6.19, a 33.73% decline from fiscal 2024.
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $9.34, a 7.34% decline from fiscal 2023.
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.08, a 25.28% decline from fiscal 2022.
- COMPASS PATHWAYS PLC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $13.49, a 62.64% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.19 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $9.34 10-K · filed 2025-02-27 | |||
| 2024-03-31 | $10.38 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $10.08 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $9.78 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $9.83 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $10.08 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $13.49 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $13.86 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $13.97 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $14.81 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $36.11 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $37.20 6-K · filed 2021-11-09 | |||
| 2021-06-30 | $40.62 6-K · filed 2021-08-11 | |||
| 2020-12-31 | $7.17 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |